FDMT
4D Molecular Therapeutics Inc
1 day chart
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The Company's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The Company is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).
Buy US stocks in Australia with $0 brokerage and trade FDMT today!
$289.73M
-
0.00%
2.11M
$8.83
$8.17
$8.79
$34.00
$5.32
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.